|
1
|
Ferlay J, Colombet M, Soerjomataram I,
Parkin DM, Piñeros M, Znaor A and Bray F: Cancer statistics for the
year 2020: An overview. Int J Cancer. Apr 5–2021.(Epub ahead of
print). View Article : Google Scholar
|
|
2
|
Balakrishnan M, George R, Sharma A and
Graham DY: Changing trends in stomach cancer throughout the world.
Curr Gastroenterol Rep. 19:362017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Smyth EC, Verheij M, Allum W, Cunningham
D, Cervantes A and Arnold D; ESMO Guidelines Committee, : Gastric
cancer: ESMO clinical practice guidelines for diagnosis, treatment
and follow-up. Ann Oncol. 27 (Suppl 5):v38–v49. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chiurillo MA: Role of the Wnt/β-catenin
pathway in gastric cancer: An in-depth literature review. World J
Exp Med. 5:84–102. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rawla P and Barsouk A: Epidemiology of
gastric cancer: Global trends, risk factors and prevention. Prz
Gastroenterol. 14:26–38. 2019.PubMed/NCBI
|
|
6
|
Rena G, Hardie DG and Pearson ER: The
mechanisms of action of metformin. Diabetologia. 60:1577–1585.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Courtois S, Lehours P and Bessède E: The
therapeutic potential of metformin in gastric cancer. Gastric
Cancer. 22:653–662. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Scarpello JHB and Howlett HCS: Metformin
therapy and clinical uses. Diab Vasc Dis Res. 5:157–167. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Daugan M, Dufaÿ Wojcicki A, d'Hayer B and
Boudy V: Metformin: An anti-diabetic drug to fight cancer.
Pharmacol Res. 113:675–685. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hua Y, Zheng Y, Yao Y, Jia R, Ge S and
Zhuang A: Metformin and cancer hallmarks: Shedding new lights on
therapeutic repurposing. J Transl Med. 21:4032023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Graham GG, Punt J, Arora M, Day RO, Doogue
MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick
CM, et al: Clinical pharmacokinetics of metformin. Clin
Pharmacokinet. 50:81–98. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Morales DR and Morris AD: Metformin in
cancer treatment and prevention. Annu Rev Med. 66:17–29. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Viollet B, Guigas B, Sanz Garcia N,
Leclerc J, Foretz M and Andreelli F: Cellular and molecular
mechanisms of metformin: An overview. Clin Sci (Lond). 122:253–270.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kato K, Gong J, Iwama H, Kitanaka A, Tani
J, Miyoshi H, Nomura K, Mimura S, Kobayashi M, Aritomo Y, et al:
The antidiabetic drug metformin inhibits gastric cancer cell
proliferation in vitro and in vivo. Mol Cancer Ther. 11:549–560.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen G, Feng W, Zhang S, Bian K, Yang Y,
Fang C, Chen M, Yang J and Zou X: Metformin inhibits gastric cancer
via the inhibition of HIF1α/PKM2 signaling. Am J Cancer Res.
5:1423–1434. 2015.PubMed/NCBI
|
|
16
|
Lu CC, Chiang JH, Tsai FJ, Hsu YM, Juan
YN, Yang JS and Chiu HY: Metformin triggers the intrinsic apoptotic
response in human AGS gastric adenocarcinoma cells by activating
AMPK and suppressing mTOR/AKT signaling. Int J Oncol. 54:1271–1281.
2019.PubMed/NCBI
|
|
17
|
Yu G, Fang W, Xia T, Chen Y, Gao Y, Jiao
X, Huang S, Wang J, Li Z and Xie K: Metformin potentiates rapamycin
and cisplatin in gastric cancer in mice. Oncotarget. 6:12748–12762.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Han G, Gong H, Wang Y, Guo S and Liu K:
AMPK/mTOR-mediated inhibition of survivin partly contributes to
metformin-induced apoptosis in human gastric cancer cell. Cancer
Biol Ther. 16:77–87. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu X: Effect of metformin combined with
chemotherapeutic agents on gastric cancer cell line AGS. Pak J
Pharm Sci. 30:1833–1836. 2017.PubMed/NCBI
|
|
20
|
Zhu M, Wang J and Zhou R: Combination of
metformin and oxaliplatin inhibits gastric cancer cell
proliferation and induces apoptosis. Acta Biochim Pol. 69:321–326.
2022.PubMed/NCBI
|
|
21
|
Fatehi-Agdam M, Vatankhah MA, Panahizadeh
R, Jeddi F and Najafzadeh N: Efficacy of metformin and
chemotherapeutic agents on the inhibition of colony formation and
Shh/Gli1 pathway: Metformin/docetaxel versus
metformin/5-fluorouracil. Drug Res (Stuttg). 71:17–25. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zarei E, Sefidi-Heris Y and Saadat I:
Synergistic effects of metformin and curcumin on cytotoxicity of
chemotherapy drugs using a gastric cancer cell line model. EXCLI J.
20:1488–1498. 2021.PubMed/NCBI
|
|
23
|
Nomenclature ISCoHC: ISCN 2020: An
International System for Human Cytogenomic Nomenclature. S. Karger
AG; London: 2020
|
|
24
|
Sun Y, Liu Y, Ma X and Hu H: The influence
of cell cycle regulation on chemotherapy. Int J Mol Sci.
22:69232021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ricci MS and Zong WX: Chemotherapeutic
approaches for targeting cell death pathways. Oncologist.
11:342–357. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Elmore S: Apoptosis: A review of
programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Duffy MJ, Synnott NC, McGowan PM, Crown J,
O'Connor D and Gallagher WM: p53 as a target for the treatment of
cancer. Cancer Treat Rev. 40:1153–1160. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Strasser A and Vaux DL: Cell death in the
origin and treatment of cancer. Mol Cell. 78:1045–1054. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nevisi F, Yaghmaie M, Pashaiefar H,
Alimoghaddam K, Iravani M, Javadi G and Ghavamzadeh A: Correlation
of HER2, MDM2, c-MYC, c-MET, and TP53 copy number alterations in
circulating tumor cells with tissue in gastric cancer patients: A
pilot study. Iran Biomed J. 24:47–53. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang BB, Wang DG, Guo FF and Xuan C:
Mitochondrial membrane potential and reactive oxygen species in
cancer stem cells. Fam Cancer. 14:19–23. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yu M, Shi Y, Wei X, Yang Y, Zhou Y, Hao X,
Zhang N and Niu R: Depletion of mitochondrial DNA by ethidium
bromide treatment inhibits the proliferation and tumorigenesis of
T47D human breast cancer cells. Toxicol Lett. 170:83–93. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pietilä M, Lehtonen S, Närhi M, Hassinen
IE, Leskelä HV, Aranko K, Nordström K, Vepsäläinen A and Lehenkari
P: Mitochondrial function determines the viability and osteogenic
potency of human mesenchymal stem cells. Tissue Eng Part C Methods.
16:435–445. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lopes-Paciencia S, Saint-Germain E, Rowell
MC, Ruiz AF, Kalegari P and Ferbeyre G: The senescence-associated
secretory phenotype and its regulation. Cytokine. 117:15–22. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Campisi J: Aging, cellular senescence, and
cancer. Annu Rev Physiol. 75:685–705. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gilbert LA and Hemann MT: DNA
damage-mediated induction of a chemoresistant niche. Cell.
143:355–366. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chambers CR, Ritchie S, Pereira BA and
Timpson P: Overcoming the senescence-associated secretory phenotype
(SASP): A complex mechanism of resistance in the treatment of
cancer. Mol Oncol. 15:3242–3255. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Moiseeva O, Deschênes-Simard X, St-Germain
E, Igelmann S, Huot G, Cadar AE, Bourdeau V, Pollak MN and Ferbeyre
G: Metformin inhibits the senescence-associated secretory phenotype
by interfering with IKK/NF-κB activation. Aging Cell. 12:489–498.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lee M and Lee JS: Exploiting tumor cell
senescence in anticancer therapy. BMB Rep. 47:51–59. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ajani JA, D'Amico TA, Bentrem DJ, Chao J,
Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Fanta P, et al:
Gastric cancer, version 2.2022, NCCN clinical practice guidelines
in oncology. J Natl Compr Canc Netw. 20:167–192. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
de Jong RG, Burden AM, de Kort S, van
Herk-Sukel MP, Vissers PA, Janssen PK, Haak HR, Masclee AA, de
Vries F and Janssen-Heijnen ML: No decreased risk of
gastrointestinal cancers in users of metformin in the netherlands;
A time-varying analysis of metformin exposure. Cancer Prev Res
(Phila). 10:290–297. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zheng J, Xie SH, Santoni G and Lagergren
J: Metformin use and risk of gastric adenocarcinoma in a Swedish
population-based cohort study. Br J Cancer. 121:877–882. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kim YI, Kim SY, Cho SJ, Park JH, Choi IJ,
Lee YJ, Lee EK, Kook MC, Kim CG, Ryu KW and Kim YW: Long-term
metformin use reduces gastric cancer risk in type 2 diabetics
without insulin treatment: A nationwide cohort study. Aliment
Pharmacol Ther. 39:854–863. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tseng CH: Metformin reduces gastric cancer
risk in patients with type 2 diabetes mellitus. Aging (Albany NY).
8:1636–1649. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Dulskas A, Patasius A, Kaceniene A,
Linkeviciute-Ulinskiene D, Zabuliene L and Smailyte G: A cohort
study of antihyperglycemic medication exposure and gastric cancer
risk. J Clin Med. 9:4352020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lee CK, Jung M, Jung I, Heo SJ, Jeong YH,
An JY, Kim HI, Cheong JH, Hyung WJ, Noh SH, et al: Cumulative
metformin use and its impact on survival in gastric cancer patients
after gastrectomy. Ann Surg. 263:96–102. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Seo HS, Jung YJ, Kim JH, Lee HH and Park
CH: The effect of metformin on prognosis in patients with locally
advanced gastric cancer associated with type 2 diabetes mellitus.
Am J Clin Oncol. 42:909–917. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lacroix O, Couttenier A, Vaes E, Cardwell
CR, De Schutter H and Robert A: Impact of metformin on gastric
adenocarcinoma survival: A Belgian population based study. Cancer
Epidemiol. 53:149–155. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Baglia ML, Cui Y, Zheng T, Yang G, Li H,
You M, Xu L, Murff H, Gao YT, Zheng W, et al: Diabetes medication
use in association with survival among patients of breast,
colorectal, lung, or gastric cancer. Cancer Res Treat. 51:538–546.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Shuai Y, Li C and Zhou X: The effect of
metformin on gastric cancer in patients with type 2 diabetes: A
systematic review and meta-analysis. Clin Transl Oncol.
22:1580–1590. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Evans JMM, Donnelly LA, Emslie-Smith AM,
Alessi DR and Morris AD: Metformin and reduced risk of cancer in
diabetic patients. BMJ. 330:1304–1305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhang J, Wen L, Zhou Q, He K and Teng L:
Preventative and therapeutic effects of metformin in gastric
cancer: A new contribution of an old friend. Cancer Manag Res.
12:8545–8554. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Cunha Júnior AD, Bragagnoli AC, Costa FO
and Carvalheira JBC: Repurposing metformin for the treatment of
gastrointestinal cancer. World J Gastroenterol. 27:1883–1904. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Sebaugh JL: Guidelines for accurate
EC50/IC50 estimation. Pharm Stat. 10:128–134. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Brooks EA, Galarza S, Gencoglu MF,
Cornelison RC, Munson JM and Peyton SR: Applicability of drug
response metrics for cancer studies using biomaterials. Philos
Trans R Soc Lond B Biol Sci. 374:201802262019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Drzewoski J and Hanefeld M: The current
and potential therapeutic use of metformin-the good old drug.
Pharmaceuticals (Basel). 14:1222021. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Chae YK, Arya A, Malecek MK, Shin DS,
Carneiro B, Chandra S, Kaplan J, Kalyan A, Altman JK, Platanias L
and Giles F: Repurposing metformin for cancer treatment: Current
clinical studies. Oncotarget. 7:40767–40780. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Saraei P, Asadi I, Kakar MA and Moradi-Kor
N: The beneficial effects of metformin on cancer prevention and
therapy: A comprehensive review of recent advances. Cancer Manag
Res. 11:3295–3313. 2019. View Article : Google Scholar : PubMed/NCBI
|
